covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Cirugía radical en el carcinoma cervical en estadio IIB o inferior. Estadificac...
Información de la revista
Vol. 46. Núm. 2.
Páginas 64-74 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 46. Núm. 2.
Páginas 64-74 (enero 2003)
Acceso a texto completo
Cirugía radical en el carcinoma cervical en estadio IIB o inferior. Estadificación clínica frente a quirurgicopatológica
Radical surgery in cervical carcinoma stage IIB or less. Clinical versus surgicalpathological staging
Visitas
5869
P. Acién
Autor para correspondencia
acien@umh.es
paciena@meditex.es

Correspondencia: Departamento de Ginecología. Campus de San Juan. Apdo. de Correos 18. 03550 San Juan. Alicante. España
, A. Barbal, F.J. Quereda, R.M. Bermejo, M. Roca, M. Acién, S.M. Eleno
Servicio de Obstetricia y Ginecología. Hospital Universitario de San Juan. Departamento/División Ginecología. Facultad de Medicina. Universidad Miguel Hernández. Campus de San Juan. Alicante. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Objetivos

Correlacionar los estadios clínico y quirurgicopatológico del cáncer cervical y analizar los resultados terapéuticos tras haber realizado cirugía radical de Wertheim-Meigs en la mayoría de los mismos con estadio IIB o inferior.

Sujetos y métodos

Análisis retrospectivo de 115 pacientes diagnosticadas de carcinoma cervical en estadio IIB o inferior entre los años 1984 y 1999; fueron operados 100 casos y se realizó cirugía radical en el 65% de los cánceres en estadio IIB; asimismo, 58 de los casos operados recibieron radioterapia; las otras 15 pacientes no operadas se trataron con radioterapia sola.

Resultados

El 21% de los casos en estadio clínico IA-IB se hallaba en realidad en un estadio quirurgicopatológico más elevado, mientras que entre aquellas pacientes operadas con un estadio clínico IIB, el 48% se encontraba realmente en un estadio más bajo. Las tasas de supervivencia actuarial a 5 años en los 100 casos operados fueron del 100% para el estadio IA, el 88% para el IB, el 100% para el IIA y el 59,4% para el IIB; a los 10 años fueron del 100, el 88, el 100 y el 52%, respectivamente. En los casos de estadio IIB no operados, las tasas de supervivencia a los 5 años fueron del 71,7 y a los 10 años del 40%. No hubo diferencias en lo que respecta a la supervivencia o recurrencias entre las pacientes en estadio IB/IIA a las que se practicó cirugía radical con o sin radioterapia posterior. Tampoco hubo diferencias en las tasas referidas al comparar la presencia o no de ganglios positivos. Sin embargo, en el estadio posquirúrgico IIB, la supervivencia a los 5 años fue del 80% si los ganglios linfáticos fueron negativos, frente al 17,8% si éstos eran positivos para cáncer.

Conclusiones

En primer lugar, en condiciones apropiadas, mediante la cirugía radical de Wertheim-Meigs se obtienen buenos resultados de supervivencia (más del 90%) en los estadios IB-IIA, que se mantienen tras la radioterapia adicional para aquellos casos con factores pronósticos adversos. En segundo lugar, la comparación entre cirugía y radioterapia no puede establecerse en el estadio clínico IIB puesto que entre los casos operados, el 47% se encontraba realmente en un estadio más bajo. Por último, en el estadio quirurgicopatológico IIB, si los ganglios linfáticos son negativos, la supervivencia es buena (80%) y las tasas de recurrencia, bajas. Por tanto, estos casos también podrían beneficiarse de la cirugía radical.

Palabras clave:
Cáncer de cérvix
Tratamiento
Cirugía radical
Radioterapia
Wertheim-Meigs
Estadificación
Summary
Objectives

To correlate the clinical and surgicalpathological stages and to analyze the therapeutic results and survival rates after Wertheim-Meigs radical surgery in patients diagnosed with invasive cervical carcinoma at stage IIB or lower.

Subjects and methods

Retrospective analysis of 115 patients diagnosed with cervical carcinoma stage IIB or less between 1984 and 1999. One hundred patients underwent surgery. Radical surgery was performed in 65% of the carcinomas at stage IIB. Fifty-eight patients who underwent surgery also received radiotherapy. The remaining 15 patients did not undergo surgery and were treated with radiotherapy alone.

Results

Twenty-one percent of patients with tumors at clinical stages IA-IB turned out to be at a higher surgical-pathological stage, while among patients who underwent surgery at clinical stage IIB, 48% were actually at a lower stage. The 5-year actuarial survival rates in the 100 surgical patients were 100% for stage IA, 88% for IB, 100% for IIA and 59.4% for IIB; at 10 years they were 100%,88%, 100% and 52%, respectively. In patients with carcinomas at stage IIB who did not undergo surgery, the 5-year survival rate was 71.7% and was 40% at 10 years. No differences were found in survival or recurrence among the patients at stages IB/IIA who had undergone Wertheim-Meigs surgery either with or without subsequent radiotherapy. No differences were found in survival or recurrence when patients with negative nodes were compared with those with positive nodes. Nevertheless, in post-surgical stage IIB, survival at 5 years was 80% if the lymph nodes were negative compared with 17.8% if the nodes were cancer-positive.

Conclusions

1) In appropriate conditions, Wertheim-Meigs radical surgery presents good survival (>90%) at stages IB/IIA, and these good results are maintained after additional radiotherapy in patients with adverse prognostic factors. 2) Comparison between surgery and radiotherapy cannot be established at clinical stage IIB, since among patients who underwent surgery, 47% were actually at a lower stage. 3) In surgical-pathological stage IIB, if lymph nodes were negative, survival was good (80%) and recurrence rates were low. Therefore, these patients could also benefit from radical surgery.

Keywords:
Cervical carcinoma
Treatment
Radical surgery
Radiotherapy
Wertheim-Meigs
Staging
El Texto completo está disponible en PDF
Bibliografía
[1.]
National Cancer Institute.
Cervical cancer. Cancer Net from the National Cancer Institute. PDQ Infomation for Health Care Professionals.
Cancerweb,
[2.]
C.W. Whitney, W. Sause, B.N. Bundy, J.H. Malfetano, E.V. Hannigan, W.C. Fowler Jr., et al.
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
J Clin Oncol, 17 (1999), pp. 1339-1348
[3.]
M. Morris, P.J. Eifel, J. Lu, P.W. Grigsby, C. Levenback, R.E. Stevens, et al.
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
N Engl J Med, 340 (1999), pp. 1137-1143
[4.]
P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, M.A. Maiman, et al.
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
N Engl J Med, 340 (1999), pp. 1144-1153
[5.]
H.M. Keys, B.N. Bundy, F.B. Stehman, L.I. Muderspach, W.E. Chafe, S. Suggs CL, et al.
Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.
N Engl J Med, 340 (1999), pp. 1154-1161
[6.]
G.M. Thomas.
Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy.
N Engl J Med, 340 (1999), pp. 1198-1200
[7.]
J. Botella.
Controversias sobre el carcinoma cervical uterino.
Acta Gin, 55 (1998), pp. 103-112
[8.]
J.Y. Charvolin, C. Nos, L. Rochefordiere Ade, V.J. Margarie, J.C. Durand, K.B. Clough.
Relevance of combined radiation and surgical treatment of early invasive carcinoma of the cervix (article in French).
Bull Cancer, 88 (2001), pp. 1207-1212
[9.]
H. Meden, A. Fattahi-Meibodi, R. Osmers, T. Krauss, W. Kuhn.
Wertheim's hysterectomy after neoadjuvant carboplatin-based chemotherapy in patients with cervical cancer stage IIB and IIIB.
Anticancer Res, 18 (1998), pp. 4575-4579
[10.]
W.T. Creasman.
New gynecologic cancer staging.
Gynecol Oncol, 58 (1995), pp. 157-158
[11.]
J. Elkas, R. Farias-Eisner.
Cancer of the uterine cervix.
Curr Opin Obstet Gynecol, 10 (1998), pp. 47-50
[12.]
O. Käser, F.A. Iklé, H.A. Hirsch.
Atlas de operaciones ginecológicas, 3.aed,
[13.]
A.L. Gerbaulet, I.R. Kunkler, R.G. Kerr, C. Haie, G. Michel, M. Prade, et al.
Combined radiotherapy and surgery: local control and complications in early carcinoma of the uterine cérvix — The Villejuif experience, 1975-84.
Radiother Oncol, 23 (1992), pp. 66-73
[14.]
F. Landoni, A. Maneo, A. Colombo, F. Placa, R. Milani, P. Perego, et al.
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.
[15.]
S.K. Tay, L.K. Tan.
Outcome of early cervical carcinoma treated by Wertheim hysterectomy with selective postoperative radiotherapy.
Ann Acad Med Singapore, 27 (1998), pp. 613-617
[16.]
I. Barillot, J.C. Horiot, J. Pigneux, S. Schraub, H. Pourquier, N. Daly, et al.
Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors.
Int J Radiat Oncol Biol Phys, 38 (1997), pp. 969-978
[17.]
P.W. Grigsby.
Stage IB1 versus IB2 carcinoma of the cervix: should the new FIGO staging system defining therapy?.
Gynecol Oncol, 62 (1996), pp. 135-136
[18.]
Y. Aoki, M. Tomita, S. Sato, M. Watanabe, H. Kase, K. Fujita, et al.
Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamous cell carcinoma of the cervix.
Gynecol Oncol, 83 (2001), pp. 263-267
[19.]
C.G.J.H. Niel, P.C.M. Koper, D.G. Visser, D. Sipkema, P.C. Levendag.
Optimizing-brachytherapy for locally advanced cervical cancer.
Int J Radiat Oncol Biol Phys, 29 (1994), pp. 373-377
[20.]
T. Arai, T. Nakano, E. Morita, K. Sakashita, K. Fukuhisa.
High-dose-rate remote afterloading in intracavitary radiation therapy for the cancer of the uterine cervix. 20-years experience.
Cancer, 69 (1992), pp. 175-180
[21.]
R. Leino, S. Greenman, V. Rantanen, P. Kiilholma, T. Salmi.
Operative treatment of advanced cervical cancer after full pelvic radiation.
Ann Chir Gynaecol (Helsinki), 83 (1994), pp. 50-53
[22.]
National Institutes of Health Consensus Development Panel.
National Institutes of Health Consensus Development Conference Statement: Cervical Cancer, April 1-3, 1996.
J Natl Cancer Inst Monogr, 21 (1996), pp. 8-13
[23.]
N. Tubiana-Mathieu, P. Bonnier, F. Delaby, X. Murraciole, C. Lejeune, D.J. Hadjadj, et al.
Treatment of carcinoma of the uterine cervix with concomitant cisplatin, 5-fluoracil and split course hyperfractionated radiotherapy.
Eur J Obstet Gynecol Reprod Biol, 77 (1998), pp. 95-100
[24.]
W.B. Jones, G.O. Mercer, J.L. Lewis Jr., S.C. Rubin, W.J. Hoskins.
Early invasive carcinoma of the cervix.
Gynecol Oncol, 51 (1993), pp. 26-32
[25.]
J.P. Curtin.
Radical hysterectomy. The treatment of choice for early-stage cervical carcinoma.
Gynecol Oncol, 62 (1996), pp. 137-138
[26.]
G.G. Kenter, B.W. Hellebrekers, K.H. Zwinderman, M. Van de Vijver, L.A. Peters, J.B. Trimbos.
The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma.
Acta Obstet Gynecol Scand, 79 (2000), pp. 72-76
[27.]
Y. Aoki, M. Sasaki, M. Watanabe, S. Sato, I. Tsuneki, H. Aida, et al.
High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
Gynecol Oncol, 77 (2000), pp. 305-309
[28.]
E.A. Boss, J.O. Barentsz, L.F. Massuger, H. Boonstra.
The role of MR imaging in invasive cervical carcinoma.
Eur Radiol, 10 (2000), pp. 256-270
[29.]
A. Hasenburg, J.K. Salama, T.J. Van, C. Amosson, J.K. Chiu, D.G. Kieback.
Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer.
Gynecol Oncol, 84 (2002), pp. 321-326
Copyright © 2003. Sociedad Española de Ginecología y Obstetricia
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos